Objective To study the efficacy and safety of sodium nitroprusside combined with levosimendan in the treatment of Refractory heart failure(RHF).Methods Using random number table method,106 patients with refractory heart failure(RHF)admitted to Wancheng District First People's Hospital from August 2019 to August 2022 were divided into control group(53 cases)and observation group(53 cases)according to 1:1 ratio.The control group was treated with sodium nitroprusside injection,and the observation group was treated with levosimendan injection on the basis of this.The therapeutic effect,cardiac function,oxidative stress index,serum inflammatory factor level and adverse reactions were com-pared between the two groups.Results The total effective rate of observation group was 92.45％higher than that of control group 77.36％(P＜0.05).Compared with control group,left ventricular ejection fraction(LEVF)and stroke output(SV)were increased,left atrial diameter(LAD)and left ventricular end-diastolic volume(LVEDV)were decreased in observa-tion group after treatment(P＜0.05).Compared with control group,after treatment,the total antioxidant state(TAS)of ob-servation group was increased,while lipid peroxidase(LPO)and myeloperoxidase(MPO)were decreased(P＜0.05).Compared with control group,homocysteine(Hey),interleukin-18(IL-18)and oligomerized domain-like receptor protein 3(NLRP3)in observation group were decreased after treatment(P＜0.05).During the treatment period,the incidence of adverse reactions in the observation group was 11.32％compared with 7.55％in the control group,with no statistical sig-nificance(P＞0.05).Conclusion Sodium nitroprusside combined with levosimendan is effective,safe and reliable in RHF patients,and can effectively inhibit inflammation and oxidative stress,thereby improving the cardiac function of pa-tients.
维普
万方数据